1)Murai H, Yamashita N, Watanabe M et al:Characteristics of myasthenia gravis according to onset-age:Japanese nationwide survey. J Neurol Sci 305:97-102, 2011
2)本村政勝:重症筋無力症の診療に役立つ話.医学と薬学59:533-543,2008
3)本村政勝:高齢発症重症筋無力症の標準的神経治療.臨床神経51:576-582,2011
4)森 秀一:神経筋接合部の維持機構と筋萎縮.医学のあゆみ244:696-703,2013
5)Cenacchi G, Papa V, Fanin M et al:Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies. J Neurol 258:746-752, 2011
6)Chan JW, Orrison WW:Ocular myasthenia:a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy. Br J Ophthalmol 91:842-843, 2007
7)Okamoto K, Ito J, Tokiguchi S et al:Atrophy of bilateral extraocular muscles. CT and clinical features of seven patients. J Neuroophthalmol 16:286-288, 1996
8)Howard JF Jr, Barohn RJ, Cutter GR et al:A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48:76-84, 2013
9)Conti-Fine BM, Milani M, Kaminski HJ:Myasthenia gravis:past, present, and future. J Clin Invest 116:2843-2854, 2006
10)Kusner LL, Kaminski HJ:The role of complement in experimental autoimmune myasthenia gravis. Ann NY Acad Sci 1274:127-132, 2012
11)Meriggioli MN, Sanders DB:Autoimmune myasthenia gravis:emerging clinical and biological heterogeneity. Lancet Neurol 8:475-490, 2009
12)川口直樹:重症筋無力症の新知見と治療.神経治療32:197-200,2015
13)Nagane Y, Utsugisawa K, Obara D et al:Efficacy of low-dose FK506 in the treatment of myasthenia gravis—a randomized pilot study. Eur Neurol 53:146-150, 2005
14)Punga AR, Stålberg E:Acetylcholinesterase inhibitors in MG:to be or not to be? Muscle Nerve 39:724-728, 2009